Eyelashes Enhancing Agents Market – Comparative Analysis by 2027

 Market Scenario

Eyelash enhancing serum is a unique formula with lash enhancement, conditioning, moisturizing, and strengthening ingredients that collaboratively works to support and improve the overall appearance of eyelashes. A plenty of temporary lash-lengthening options are available in the market such as mascara and false eyelashes, which are available in the market, but there has been an influx of eyelash serums in stores that promise to strengthen and grow those tiny hairs. These eyelash enhancers have become increasingly popular due to their effective functional feature that turns drab, sparse, and brittle eyelashes into attractive and long eyelashes by the simple process of applying serums to the eyelash area. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4862

The global eyelashes enhancing agents market is growing moderately due to increasing prevalence of eye inflammations such as madarosis and blepharitis. Additionally, a shift in trend towards the natural eyelash enhancer agent, and continuous uptake of come higher medical dosages cause loss of eyelashes is likely to drive the market growth over the review period.

Breast cancer patients suffer from madarosis due to continuous session of intra-arterial chemotherapy. To cure this disease, a formulation of eyelash enhancer such as bimatoprost is used that maximizes eyelash and minimizes intraocular side effect. In case of blepharitis, there is loss of eyelashes occurs due to the presence of bacteria and oily flakes at the base of eyelashes. Blepharitis is a common disease, especially, among people who have oily skin, dandruff or dry eyes. According to International Journal of Development Research, blepharitis accounted for 700,000 patient visits in the US in 2014. Patients who have blepharitis take eyelash enhancer such as biotin as part of treatment. In some cases, blepharitis also causes loss of eyelashes (madarosis).

However, side-effects of eyelashes enhancer agents may affect the growth of the global eyelashes enhancing agents market, negatively.

The global eyelashes enhancing agents market is expected to grow at a CAGR of 5.83% during the forecast period 2017-2023. 

The global eyelashes enhancing agents market has been segmented on the basis of application, content, type, and lastly, region. The application-based segmentation of this market segments the market into repairing damaged eyelashes, nourishing eyelashes, and others. Based on content, the market has been segmented into bimatoprost, enhancer serum, herbal remedy, isopropyl cloprostenate, lash-building serum, skin care ingredients, and others.  The skin care ingredients have been sub-segmented into biotin, panthenol, polypeptides, and others. By type, the market has been segmented into curling, lengthening, volumizing, and others. Curling has been estimated to emerge as the fastest growing segment during the forecast period.

The regional segmentation of the global eyelashes enhancing agents market segments the market into the Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA). The Americas segment holds the biggest share in the global market due to the huge development in the region’s cosmetic industry, presence of strong economic conditions, presence of many key market players, and focus by research institutions on research and development (R&D) in order to update the technology for new and advanced eyelashes enhancing agents. Due to advanced technology and the presence of many strong economies, North America is a bigger market than South America. The major country-specific markets in this region are the USA and Canada.

Europe is the second largest market due to the high density of population, changing lifestyle, growing cosmetics industry, increasing demand for eyelashes enhancing agents, and well-developed technology. Due to similar reasons as the Americas, Western Europe is a bigger market than Eastern Europe. In this region, the major country-specific markets are France, Germany, Italy, and the UK, followed by the remaining countries of Western as well as Eastern Europe.

The Asia Pacific region is the fastest growing regional market, and during the forecast period, it is expected to grow at a 6.26% CAGR. The main factor driving the market growth in this region is the presence of a number of developing nations like China and India in this region. In these countries, the growth of the cosmetics industry is aiding the market growth. Other factors contributing to market growth are the increasing prevalence of eye inflammations and the demand for various eyelashes enhancing agents. Other pivotal country-specific markets in this region are Japan and South Korea, followed by the remaining countries of Asia Pacific.

The MEA region holds the lowest market share due to less availability of medical facilities and lack of healthcare facilities. However, countries such as Kuwait and Qatar are focusing more on the healthcare and cosmetic industries. They are also developing medical facilities, which might create a stable market in this region during the forecast period.

Key Players:

The key players in the global eyelashes enhancing agents market include Allergan PLC (Republic of Ireland), Athena Cosmetics Inc. (USA), Beauty Essentials LLC (USA), Estee Lauder (USA), Grande Cosmetics LLC (USA), Rodan & Fields LLC (USA), and Skin Research Laboratories (USA).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/eyelashes-enhancing-agents-market-4862 

Diabetes Pen Market Growth, Demands, CAGR, Sales Volume, Opportunities, Types, Applications and Forecast up to 2027

 Insulin is a hormone produced by the pancreas.  A diabetes pen is used to inject insulin for the treatment of diabetes. It is composed of an insulin cartridge (integrated or bought separately) and a dial to measure the dose, and is used with disposable pen needles to deliver the dose. Diabetes is a major chronic disease across the globe. Changing lifestyle, high intake of carbohydrates and sugar, and obesity are major factors elevating the prevalence of the disease. Increasing prevalence of diabetes and obesity and growing demand for diabetes pen drive the market for diabetes pen.

The global diabetes pen market is expected to grow at a CAGR of approximately 8.45% during the forecast period 2017-2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/564 

Market Highlights
The global diabetes pens market is estimated to progress over the upcoming years due to increasing prevalence of diabetes and corresponding rise in the patients in need of regular insulin administration. Introduction of insulin pens and smart insulin pens have significantly contributed to rapid proliferation of diabetes injection pens market. Growing incidence of needle stick injury corresponding to the growing users of insulin injections is additionally driving patients to opt for diabetes injection pens.  
During forecast period 2017 to 2023, the global diabetes pen market is expected to reach USD 9.85 billion by 2023 at a CAGR of 8.45%
Taste the market data and market information presented through more than 52 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Diabetes Pen Market Research Report –Global Forecast till 2023.”

Global Diabetes Pen Market Players
Key players in diabetes pen market: AstraZeneca (U.K), Teruma Medical Corporation (Japan), Greinier Bio One International GmBH (U.S.), F. Hoffman La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Bayer Cropscience Ltd. (Germany), and HTL STREFA SA (Poland)

Regional Analysis
Globally, diabetes pen market consists of four regions: North America, Europe, Asia Pacific. and Middle East & Africa. North America is expected to be the largest market for diabetes pen. Reimbursement for diabetes management and technological advancement in production of diabetes pens to administer accurate and safe dose drive this market.  Extensive research and development to enhance the quality of diabetes pens as well as to increase their reliability is also another reason for the growth of this market in North America. Large number of diabetes pen users have been found in European countries, especially in the U.K. leading to an increase in their demand.  Asia Pacific is expected to be fastest growing market for diabetes pen with India being the largest market due to growing expenditure in the healthcare to curb lifestyle disease and improved healthcare infrastructure. The Middle East & Africa, major drivers for rise in this market are initiative to control the elevated levels of diabetes and awareness regarding lifestyle diseases.

Segmentation:

The global diabetes pen market is segmented on the basis of product, which includes insulin pens and insulin pen needle. On the basis of usage, the market is segmented into includes reusable pens and disposable pens used of diabetes pen. And on the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online sales, and diabetes clinics.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/global-diabetes-pen-market-564 

Antihistamine Drugs Market Report 2020 with Key Players, Regions, Trends, Market Growth, SWOT Analysis and Forecast to 2027

 Antihistamines are drugs mainly used for treating allergies. They are also used to treat motion sickness, insomnia and anxiety. They work by acting against a chemical called histamine which leads to many allergic symptoms. Antihistamines may cause side effects such as dizziness, dry mouth, nervousness, irritability, blurry vision and decreased appetite.

The global antihistamine drugs market is expected to grow at a CAGR of 9.8% during the forecast period and is estimated to reach USD 280 million by 2027.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4266 

Major players in antihistamine drugs market

Some of the key players in the global market are Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)

Regional Analysis

The global antihistamine drugs market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas dominate the global antihistamine drugs market. It comprises of two regions namely North America and South America. North America in the largest market owing to development of new antihistamine drugs by major market players for the treatment of allergies.

In Europe, rising awareness about sedating and non-sedating antihistamine drugs and their side effects as well as precautionary awareness drives this market. Furthermore, increasing prevalence of allergy rhinitis is found in European nations which further propels the market growth.

Asia Pacific is the fastest growing and potential market for antihistamine drugs, whose growth is attributed to the rising awareness about allergic conditions and availability of medications for its treatment.

The Middle East & Africa is expected witness steady growth owing to the rising demand for drugs and healthcare resources in this region.

Segmentation

The global antihistamine drugs market is segmented on the basis of types which includes sedating and non-sedating antihistamines. Sedating antihistamines are further sub-segmented into brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, carbinoxamine and others. Non-sedating antihistamines are further sub-segmented into fexofenadine, loratadine, loratadine odt, and others.

On the basis of route of administration, the market is segmented into oral route, parenteral route and rectal route. Parenteral route segmented is further sub-segmented into intramuscular, subcutaneous and intravenous route.

On the basis of indication, the market is segmented into allergy, urticaria, dermatitis, and others. And on the basis of end users, the market is segmented into hospitals, clinics, pharmaceutical companies and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/antihistamine-drugs-market-4266 

Global Laboratory Equipment Market to Witness Steady Growth through 2027

 Market Forecast

Global Laboratory Equipment Market is expected to hold a value of USD 58,960 Million by 2025 at a CAGR of 7.3%.

Market Synopsis

There has been a high level of technological improvement in laboratory equipment in the past few years, which is fueling the global market growth. Also, as laboratory equipment is used rigorously for testing and research purposes, companies are investing in this market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8365 

Laboratory equipment are the tools used by lab technicians or scientists to work in a laboratory. These instruments and devices aid in various tasks such as preparation of cell culture mediums for research, analysis of the biological samples of patients, studying tissues for diagnosis of various diseases, and others.

The growth of the global laboratory equipment market is driven by various factors such as increasing demand for lab automation, the shift from lab-based diagnosis to the point of care diagnosis, increasing biomedical research, and rising innovations by major players. However, the lack of laboratory setups in developing countries is projected to hamper the growth of the global laboratory equipment market.

The global laboratory equipment market trends are currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in October 2018, Eppendorf AG presents first internally developed the CO2 incubator.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the rising per capita healthcare expenditure. The laboratory equipment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European laboratory equipment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The laboratory equipment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing clinical laboratories and increasing pool of patient population, the market in Asia-Pacific is expected to be the fastest-growing. The laboratory equipment market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global laboratory equipment market has been segmented based on product type, application, and end user.

The market, based on product type, has been divided into incubators, centrifuges, spectrometers, scopes, sonicators, autoclaves, and others. The incubators segment is likely to be the largest during the review period due to the growing use of this device in various areas of testing. The spectrometers segment is predicted to be the fastest-growing due to the increasing product launches in the market. For instance, in April 2018, Bruker launched INVENIO Fourier Transform Infrared (FT-IR) research spectrometer.

The global laboratory equipment market has been segmented, on the basis of application, into biochemistry, endocrinology, microbiology, hematology, genetic testing, and others. The biochemistry segment is expected to hold the majority share of the market owing to the wide number of biochemical tests carried out in the laboratories. The endocrinology segment is expected to be the fastest-growing due to the rising patient pool, coupled with the increasing number of tests.

The end users of the market are hospitals and clinics, diagnostic centers, and others. The hospitals and clinics segment is expected to hold the largest share of the market due to the increasing number of hospitals and clinics using laboratory equipment. The diagnostic centers segment is expected to be the fastest-growing owing to the increased preference of medical professionals for carrying out diagnostic tests.

Key Players

Some of the key players in the global laboratory equipment market are Agilent Technologies, Inc. (US), BD (US), Beckman Coulter, Inc. (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Eppendorf AG (Germany), F. Hoffmann LA-Roche AG (Switzerland), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific Inc. (US), and Waters (US), among others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/laboratory-equipment-market-8365   

Alpha-1 Antitrypsin Deficiency Treatment Market size in terms of volume and value 2020-2027

 Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%.

Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8319 

Market Synopsis

Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the global alpha-1 antitrypsin deficiency treatment market trends.

Strategic mergers & acquisitions are also projected to boost market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.

High unmet medical needs in developing economies are directly providing lucrative opportunities for the market growth.

Segmentation

By Drugs:

• Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.
• Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
• Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
• Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.

By Route of Administration:

• Oral: The segment is expected to hold the largest market share.
• Intravenous: The segment is expected to grow at the fastest CAGR.
• Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
• Others: Subcutaneous and intramuscular routes of administration.

By Distribution Channel:

• Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
• Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
• Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.

By Region

• Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

• Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

• Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.

• Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

• Kamada Pharmaceuticals (Israel)
• CSL Behring LLC (US)
• Grifols, S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• GlaxoSmithKline plc (UK)
• Boehringer Ingelheim GmbH (Germany)
• AstraZeneca (UK)
• Vectura Group plc (UK)
• Pfizer Inc. (US)
• Mylan Inc. (US)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319 

Future of Blockchain in Pharmaceutical Supply Chain Management Market Analyzed in a New Study 2027

 The Global Blockchain in Pharmaceutical Supply Chain Management Market is expected to register a CAGR of 22.5% during the forecast period of 2019 to 2024.

A blockchain solution can make a substantive difference to the pharmaceutical supply chain. At every stage of the supply chain process, barcodes would be scanned and recorded onto a blockchain ledger system which, in sequence, records and creates an audit trail of the drug journey. Sensors can also be combined into the supply chain, with temperature or humidity being noted onto the ledger system. This is most important for drugs requiring fridge storage, such as insulin or expensive, specially manufactured medicines.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8009 

Furthermore, through the use of blockchain, the supply chain process of the drugs can become more secure and streamlined. Every delivery can be tracked, with the delivery driver traced through biometric measures. Every checkpoint concerning the drugs supply is recorded and traced via biometric measures, 2d barcode scans, or sensor technology. As the drug is tracked from its manufacturing unit to the patient, the whole of the drug supply chain becomes seamless, precise, audited, and safe.

Segmentation

The global blockchain in pharmaceutical supply chain management is segmented on the basis of application, end user, and region.

On the basis of application, the global blockchain in pharmaceutical supply chain management market is segmented into product traceability, risk and compliance management, payment & settlement, others. The market by end user is segmented into manufacturers, distributors, healthcare providers

On the bases of region, the global blockchain in pharmaceutical supply chain management market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold the largest market share and the Middle East & Africa with a low market share during the forecasted period.

Key Players

Some of the key players in the global blockchain in pharmaceutical supply chain management market are IBM, Microsoft, SAP SE, Oracle, Tibco Software, Auxesis Group, Omnichain, Vechain Foundation, Chainvine, Applied Blockchain, AWS, Huawei, Guardtime, BTL Group, Bitfury, Digital Treasury Corporation, Blockverify, Nodalblock, Peer Ledger and others.

Regional Analysis

The healthcare sector and its supporting IT infrastructure are going through dramatic changes, all of which impact the claims management process and lead to improving the technology. Many healthcare organizations use robotic process automation, intelligent EDI integration, insurance discovery, and patient solutions all within their workflow platform to dramatically enhance the overall process. The adoption of various software has increased profit.

Infrastructure and technology are continuously evolving in developing regions such as Asia-Pacific. A number of different multinational and local companies are involved in developing their markets in this region owing to the developing economy and increasing government support. An increasing number of healthcare companies have provided a good opportunity for the development of the blockchain in pharmaceutical supply chain management market.

Furthermore, in the United States, the Drugs Quality and Safety Act (DQSA) was promoted by Congress on November 27, 2013. This outlines the steps to be taken to develop an interoperable electronic supply chain management system. This will strengthen the FDA's capability to protect consumers from exposure to drugs that could be fake or from the black market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/blockchain-pharmaceutical-supply-chain-management-market-8009 

Pneumoconiosis Market Statistics Analysis 2020-2027

 Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4639 

The global pneumoconiosis market is expected to grow at a CAGR of 6.8% during forecast period. 

Regional Analysis

The Americas dominate the global pneumoconiosis pronunciation market owing to a large patient population, strong government support for research & development, and high healthcare spending. Smoking increase the risk of causing this disease. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is estimated around 36.5 million adults in the United States currently smoke cigarettes. Moreover, changing lifestyle and increasing number of smokers has fuelled the growth of the market. 

Europe has the second leading market in global pneumoconiosis market which is followed by Asia Pacific. Asia Pacific is the fastest growing market for pneumoconiosis. As per statistics, more than half of the china population smoke. China and India contribute a major share in the Asia Pacific pneumoconiosis market. Increasing geriatric population and increasing air pollution in this region have fuelled the growth of the market.

The Middle East and Africa contribute the least in the growth of global pneumoconiosis market. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition. However the growth of the Africa market is high due to the presence of opportunities for the development of the market.

Segmentation

The global pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.

On the basis of type, the market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.

On the basis of cause, the market is categorized into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.

On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.

On the basis of end user, the market is segmented into hospital, clinics, and others. 

Key Players

The key players for the global pneumoconiosis market Abbott (US) Eli Lilly (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (US), AstraZeneca (UK), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pneumoconiosis-market-4639